As of 2025-07-01, the Relative Valuation of Apellis Pharmaceuticals Inc (APLS) is (37.51) USD. This relative valuation is based on P/E multiples. With the latest stock price at 17.87 USD, the upside of Apellis Pharmaceuticals Inc based on Relative Valuation is -309.9%.
The range of the Relative Valuation is (30.29) - (42.00) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.5x - 23.6x | 19.6x |
| Forward P/E multiples | 17.0x - 28.2x | 22.6x |
| Fair Price | (30.29) - (42.00) | (37.51) |
| Upside | -269.5% - -335.0% | -309.9% |
| Date | P/E |
| 2025-06-30 | -9.73 |
| 2025-06-27 | -9.79 |
| 2025-06-26 | -10.34 |
| 2025-06-25 | -10.33 |
| 2025-06-24 | -10.46 |
| 2025-06-23 | -9.90 |
| 2025-06-20 | -9.94 |
| 2025-06-18 | -9.98 |
| 2025-06-17 | -9.98 |
| 2025-06-16 | -10.28 |
| 2025-06-13 | -10.58 |
| 2025-06-12 | -10.82 |
| 2025-06-11 | -10.83 |
| 2025-06-10 | -11.00 |
| 2025-06-09 | -10.89 |
| 2025-06-06 | -10.83 |
| 2025-06-05 | -10.73 |
| 2025-06-04 | -10.40 |
| 2025-06-03 | -10.57 |
| 2025-06-02 | -10.75 |
| 2025-05-30 | -9.51 |
| 2025-05-29 | -9.78 |
| 2025-05-28 | -9.44 |
| 2025-05-27 | -9.49 |
| 2025-05-23 | -9.80 |
| 2025-05-22 | -9.99 |
| 2025-05-21 | -9.79 |
| 2025-05-20 | -10.40 |
| 2025-05-19 | -9.93 |
| 2025-05-16 | -9.80 |
| 2025-05-15 | -9.19 |
| 2025-05-14 | -9.38 |
| 2025-05-13 | -9.71 |
| 2025-05-12 | -9.84 |
| 2025-05-09 | -9.72 |
| 2025-05-08 | -10.01 |
| 2025-05-07 | -10.11 |
| 2025-05-06 | -10.74 |
| 2025-05-05 | -11.23 |
| 2025-05-02 | -11.43 |
| 2025-05-01 | -11.28 |
| 2025-04-30 | -10.79 |
| 2025-04-29 | -10.23 |
| 2025-04-28 | -10.09 |
| 2025-04-25 | -9.83 |
| 2025-04-24 | -9.86 |
| 2025-04-23 | -9.83 |
| 2025-04-22 | -9.76 |
| 2025-04-21 | -10.13 |
| 2025-04-17 | -10.23 |